Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia
Public ClinicalTrials.gov record NCT06179108. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate the Antipsychotic Efficacy and Safety of LB-102 in the Treatment of Adult Patients With Acute Schizophrenia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center inpatient study to evaluate the efficacy and safety of LB-102 in adult patients diagnosed with acutely exacerbated schizophrenia. To determine whether LB-102 administered to patients with acutely exacerbated schizophrenia demonstrates antipsychotic efficacy, as determined by a change from Baseline on the Positive and Negative Syndrome Scale (PANSS) total score, compared to placebo at 28 days. The secondary objectives of the study are to evaluate improvement in CGI-S, safety and tolerability, and pharmacokinetics.
Study identification
- NCT ID
- NCT06179108
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 359 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 29, 2023 (Actual)
- Primary completion
- Dec 4, 2024 (Actual)
- Completion
- Dec 4, 2024 (Actual)
- Last update posted
- Oct 22, 2025
2023 – 2024
United States locations
- U.S. sites
- 25
- U.S. states
- 10
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pillar Clinical Research | Bentonville | Arkansas | 72712 | — |
| Woodland Internation Research Group | Little Rock | Arkansas | 72211 | — |
| Woodland Research Northwest | Rogers | Arkansas | 72758 | — |
| CelExel Clinical Innovations | Bellflower | California | 90706 | — |
| Synexus | Cerritos | California | 90703 | — |
| ProScience Research Group | Culver City | California | 90230 | — |
| CelExel CNS | Garden Grove | California | 92845 | — |
| Synergy Research | Lemon Grove | California | 91945 | — |
| CenExel CIT Riverside | Riverside | California | 92506 | — |
| NRC Research Institute | Santa Ana | California | 92705 | — |
| Behavioral Clinical Research, Inc. | Hollywood | Florida | 33021 | — |
| CenExel RCA | Hollywood | Florida | 33024 | — |
| Segal Institute for Clinical Research | Miami Lakes | Florida | 33016 | — |
| CenExel ACMR | Atlanta | Georgia | 30331 | — |
| CenExel iResearch | Decatur | Georgia | 30030 | — |
| Uptown Research Institute | Chicago | Illinois | 60640 | — |
| Pillar Clinical Research | Chicago | Illinois | 60641 | — |
| CenExel CBH | Gaithersburg | Maryland | 20877 | — |
| CenExel HRI | Berlin | New Jersey | 08009 | — |
| Richmond Behavioral Associates | Staten Island | New York | 10314 | — |
| Midwest Clinical Research Center | Dayton | Ohio | 45417 | — |
| Neuro-Behavioral Clinical Research | North Canton | Ohio | 44720 | — |
| Community Clinical Research | Austin | Texas | 78754 | — |
| InSite Clinical Research | DeSoto | Texas | 75115 | — |
| Pillar Clinical Research | Richardson | Texas | 75080 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06179108, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 22, 2025 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06179108 live on ClinicalTrials.gov.